Article ; Online: Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.
2021 Volume 105, Page(s) 598–605
Abstract: Objective: There is an urgent need for effective treatments to prevent or attenuate lung and systemic inflammation, endotheliitis, and thrombosis related to COVID-19. This study aimed to assess the effectiveness of a multidrug-therapy consisting of ... ...
Abstract | Objective: There is an urgent need for effective treatments to prevent or attenuate lung and systemic inflammation, endotheliitis, and thrombosis related to COVID-19. This study aimed to assess the effectiveness of a multidrug-therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid ("TNR4" therapy) to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. Design and methods: A comparative effectiveness study was performed among 768 confirmed SARS-CoV-2 cases aged 18-80 years, who received ambulatory care at the Ministry of Health of Tlaxcala. A total of 481 cases received the TNR4 therapy, while 287 received another treatment (comparison group). All participants received home visits and/or phone calls for clinical evaluation during the 14 days after enrollment. Results: Nearly 85% of cases who received the TNR4 recovered within 14 days compared to 59% in the comparison group. The likelihood of recovery within 14 days was 3.4 times greater among the TNR4 group than in the comparison group. Patients treated with TNR4 had a 75% and 81% lower risk of being hospitalized or death, respectively, than the comparison group. Conclusions: TNR4 therapy improved recovery and prevented the risk of hospitalization and death among ambulatory COVID-19 cases. |
---|---|
MeSH term(s) | Acetates/therapeutic use ; Adult ; Aged ; Aged, 80 and over ; Antiviral Agents/therapeutic use ; Aspirin/therapeutic use ; Azithromycin/therapeutic use ; Cyclopropanes/therapeutic use ; Drug Therapy, Combination ; Hospitalization ; Humans ; Ivermectin/therapeutic use ; Male ; Mexico ; Middle Aged ; Quinolines/therapeutic use ; SARS-CoV-2 ; Sulfides/therapeutic use ; Treatment Outcome ; Young Adult ; COVID-19 Drug Treatment |
Chemical Substances | Acetates ; Antiviral Agents ; Cyclopropanes ; Quinolines ; Sulfides ; Ivermectin (70288-86-7) ; Azithromycin (83905-01-5) ; montelukast (MHM278SD3E) ; Aspirin (R16CO5Y76E) |
Language | English |
Publishing date | 2021-02-10 |
Publishing country | Canada |
Document type | Journal Article |
ZDB-ID | 1331197-9 |
ISSN | 1878-3511 ; 1201-9712 |
ISSN (online) | 1878-3511 |
ISSN | 1201-9712 |
DOI | 10.1016/j.ijid.2021.02.014 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 4516: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.